
{| class="wikitable" |+ | colspan="4" |

1.  格式問題，請參考其他同性質文章（如[利福平](../Page/利福平.md "wikilink")）來修改格式。請善用連結翻譯器
2.  數字和英文不要用全形（例：１２３４５），請使用半形數字（12345），內文的括號才用全形
3.  不要修改副標題格式，我上次有示範給你看要怎麼改了，如果忘記請舉手發問
4.  「approved for medical use」是指「核准做為醫療用途」，跟你翻譯的有點差異
5.  「在世界衛生組織的基本藥物清單裡，醫療衛生系統.中，恩替卡韋為最有效和安全的藥物」請重新組織

|}

## 醫療用途

恩替卡韋**Entecavir**
(**ETV**)，以商品名博路定銷售，是一種[抗病毒藥物](../Page/抗病毒药物.md "wikilink")，用於治療感染[B型肝炎病毒](../Page/乙型肝炎病毒.md "wikilink")(HBV)的人。\[1\]也用於[愛滋病和HBV抗逆轉錄病毒藥物](https://zh.wikipedia.org/wiki/艾滋病 "wikilink")[抗反轉錄病毒藥物](../Page/抗反轉錄病毒藥物.md "wikilink")。\[2\]

恩替卡韋為藥片或藥水，以口服方式食用。\[3\]

普遍的副作用包含頭痛，噁心，[高血糖和腎功能下降](../Page/高血糖.md "wikilink")。\[4\]如果停止藥物，嚴重的副作用包跨
，[酸性酸中毒](https://zh.wikipedia.org/wiki/乳酸性酸中毒 "wikilink")，和[肝炎](https://zh.wikipedia.org/wiki/肝炎 "wikilink")。\[5\]

然而，在懷孕期間似無不會影響，但這種用途尚未得到很好的研究。\[6\]恩替卡韋是藥物核苷逆轉錄酶抑製劑[nucleoside reverse
transcriptase
inhibitors](https://zh.wikipedia.org/wiki/nucleoside_reverse_transcriptase_inhibitors "wikilink")
(NRTIs)的家族。\[7\]\[8\]恩替卡韋可以防止來自阻斷逆轉錄酶的乙型肝炎病毒。

2005年，恩替卡韋已核准做為醫療用途。\[9\]在[世界衛生組織基本藥物標準清單或是](../Page/世界卫生组织基本药物标准清单.md "wikilink")中，恩替卡韋為最有效和最安全的藥物。\[10\]在美國恩替卡韋還不能作為通用名藥物到2015年。\[11\]2016年恩替卡韋在美國一個月的供應量主要批發價為392美元。\[12\]

在美國，2015年前恩替卡韋不能以[通用名藥物販售](../Page/通用名药物.md "wikilink")。從2016年起恩替卡韋是wholesale
price

恩替卡韋**Entecavir** (**ETV**), 以商品名博路定銷售，是一種 **抗病毒藥物**, is an used in the
treatment of infection.\[13\] In those with both and HBV should also be
used. Entecavir is taken by mouth as a tablet or solution.

Common side effects include headache, nausea, , and decreased kidney
function. Severe side effects include,, and if the medication is
stopped. While there appears to be no harm from use during pregnancy,
this use has not been well studied. Entecavir is in the family of
medications. It prevents the hepatitis B virus from multiplying by
blocking [reverse
transcriptase](https://zh.wikipedia.org/wiki/reverse_transcriptase "wikilink").\[14\]

Entecavir was approved for medical use in 2005. It is on the [World
Health Organization's List of Essential
Medicines](../Page/世界卫生组织基本药物标准清单.md "wikilink"),
the most effective and safe medicines needed in a

In the United States as of 2015 it is not available as a [generic
medication](../Page/通用名药物.md "wikilink"). The wholesale price is as of
2016 in the United States.

## 醫藥用途

恩替卡韋主要用於長期為B肝的成年患者、兩歲幼童或年齡較大的小孩。病毒複製活耀會有活動性疾病的跡象能使肝酶升高。\[15\]恩替卡韋也適用在肝臟移植手術後的病患，可預防再次感染B型肝炎病毒，\[16\]和治療愛滋病病毒的病患。恩替卡韋對B型肝炎病毒的活性較弱，但不推薦用在同時感染B型肝炎病毒和愛滋病病毒的病患，因為沒有方案可以完全抑制抗-愛滋病病毒。\[17\]

as it may select for resistance to lamivudine and emtricitabine in
HIV.\[18\]

Entecavir is mainly used to treat chronic hepatitis B infection in
adults and children 2 years and older with active viral replication and
evidence of active disease with elevations in liver enzymes.\[19\] It is
also used to prevent HBV reinfection after liver transplant\[20\] and to
treat HIV patients infected with HBV. Entecavir is weakly active against
HIV, but is not recommended for use in HIV-HBV co-infected patients
without a fully suppressive anti-HIV regimen\[21\] as it may select for
resistance to lamivudine and emtricitabine in HIV.\[22\]

The efficacy of entecavir has been studied in several randomized,
double-blind, multicentre trials. Entecavir by mouth is effective and
generally well tolerated treatment.\[23\]

### 懷孕和母乳

It is considered [pregnancy category](../Page/懷孕分級.md "wikilink") C in
the United States, and currently no adequate and well-controlled studies
exist in pregnant women.\[24\]



## 副作用

The majority of people who use entecavir have little to no side
effects.\[25\] The most common side effects include headache, fatigue,
dizziness, and nausea.\[26\] Less common effects include [trouble
sleeping](../Page/失眠.md "wikilink") and gastrointestinal symptoms such
as sour stomach, diarrhea, and vomiting.\[27\]

Serious side effects from entecavir include lactic acidosis, , , and
.\[28\]

Laboratory tests may show an increase in [alanine
transaminase](../Page/谷丙转氨酶.md "wikilink") (ALT),
[hematuria](../Page/血尿.md "wikilink"), , and an increase in
[lipase](../Page/脂酶.md "wikilink").\[29\] Periodic monitoring of hepatic
function and hematology are recommended.\[30\]

## 作用機制

Entecavir is a ,\[31\] or more specifically, a
[deoxyguanosine](https://zh.wikipedia.org/wiki/脫氧鳥苷 "wikilink")  that
belongs to a class of s and inhibits [reverse
transcription](../Page/逆转录酶.md "wikilink"), [DNA
replication](../Page/DNA复制.md "wikilink") and
[transcription](../Page/转录.md "wikilink") in the  process. Other
nucleoside and nucleotide analogues include
[lamivudine](../Page/拉米夫定.md "wikilink"), , [adefovir
dipivoxil](../Page/阿德福韦.md "wikilink"), and
[tenofovir](../Page/替诺福韦二吡呋酯.md "wikilink").

Entecavir reduces the amount of HBV in the blood by reducing its ability
to multiply and infect new cells.\[32\]

## 服用方法

Entecavir is taken by mouth as a tablet or solution. Doses are based on
a person's weight.\[33\] The solution is recommended for children more
than 2 years old who weigh up to 30 kg. Entecavir is recommended on an
empty stomach at least 2 hours before or after a meal, generally at the
same time every day. It is not used in children less than 2 years old.
Dose adjustments are also recommended for people with decreased kidney
function.\[34\]

## 歷史

  - 1992: SQ-34676 at Squibb as part of anti-herpes virus program\[35\]
  - 1997: BMS 200475 developed at BMS pharmaceutical research institute
    as antiviral nucleoside analogue à Activity demonstrated against
    HBV, HSV-1, HCMV, VZV in cell lines & no or little activity against
    HIV or influenza\[36\]
  - Superior activity observed against HBV pushed research towards BMS
    200475, its base analogues and its enantiomer against HBV in
    HepG2.2.15 cell line\[37\]
  - Comparison to other NAs, proven more selective potent inhibitor of
    HBV by virtue of being Guanine NA\[38\]
  - 1998: Inhibition of hepadnaviral polymerases was demonstrated in
    vitro in comparison to a number of NAs-TP\[39\]
  - Metabolic studies showed more efficient phosphorylation to
    triphosphate active form\[40\]
  - 3-year treatment of woodchuck model of CHB à sustained antiviral
    efficacy and prolonged life spans without detectable emergence of
    resistance\[41\]
  - Efficacy \# LVD resistant HBV replication in vitro\[42\]
  - Superior activity compared to LVD in vivo for both HBeAg+ & HBeAg−
    patients\[43\]\[44\]
  - Efficacy in LVD refractory CHB patients\[45\]
  - Entecavir was approved by the U.S.
    [FDA](../Page/美国食品药品监督管理局.md "wikilink") in
    March 2005.

### 專利資訊

Bristol-Myers Squibb was the original patent holder for Baraclude, the
brand name of entecavir in the US and Canada. The drug patent expiration
for Baraclude was in 2015.\[46\]\[47\] On August 26, 2014, [Teva
Pharmaceuticals USA](../Page/梯瓦.md "wikilink") gained FDA approval for
generic equivalents of Baraclude 0.5 mg and 1 mg tablets;\[48\]
received such approval on August 21, 2015;\[49\] and  on August 26,
2015.\[50\]

## 參考文獻

## 外部連結

  - [PubMed Health page on
    Entecavir](https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0010112/)
  - [Baraclude U.S. website](http://www.baraclude.com/)

[Category:百时美施贵宝](https://zh.wikipedia.org/wiki/Category:百时美施贵宝 "wikilink")
[Category:核苷类似物逆转录酶抑制剂](https://zh.wikipedia.org/wiki/Category:核苷类似物逆转录酶抑制剂 "wikilink")
[Category:嘌呤](https://zh.wikipedia.org/wiki/Category:嘌呤 "wikilink")
[Category:Hepatotoxins](https://zh.wikipedia.org/wiki/Category:Hepatotoxins "wikilink")
[Category:世界卫生组织基本药物](https://zh.wikipedia.org/wiki/Category:世界卫生组织基本药物 "wikilink")
[Category:RTT](https://zh.wikipedia.org/wiki/Category:RTT "wikilink")
[Category:环戊基化合物](https://zh.wikipedia.org/wiki/Category:环戊基化合物 "wikilink")
[Category:烯烃](https://zh.wikipedia.org/wiki/Category:烯烃 "wikilink")

1.

2.
3.
4.
5.
6.

7.
8.

9.
10.

11.

12.  Data.Medicaid.gov|accessdate=6 December
    2016|archiveurl=[https://web.archive.org/web/20161130035804/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-11-30/rfpb-hznz|archivedate=30](https://web.archive.org/web/20161130035804/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-11-30/rfpb-hznz%7Carchivedate=30)
    November 2016|website=Centers for Medicare and Medicaid
    Services|deadurl=no|df=}}

13.
14.
15.
16.
17.
18.
19.
20.

21.

22.

23.

24.

25.

26.
27.

28.
29.

30.
31.

32.

33.

34.
35. Slusarchyk, W. A., A. K. Field, J. A. Greytok, P. Taunk, A. V.
    Tooumari, M. G. Young, and R. Zahler.
    4-Hydroxy-3-(hydroxymethyl)-2-methylcyclopentyl purines and
    pyrimidines, a novel class of anti-herpesvirus agents. Abstract from
    the Fifth International Conference on Antiviral Research. Antivir
    Res 1992.17(Suppl. 1):98

36.

37.
38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.